Clinical Efficacy and Safety Preliminary Study of Sulbactam Sodium in Treatment of Extensively Drug Resistant Acinetobacter baumannii Infection
GUO Xiao-long1,2, WU Bin1, ZHANG Qian1, HU Yang1, MEI Dan1, ZHANG Bo1*
1. Peking Union Medical College Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College,Beijing 100730,China;
2. Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing 100091,China
OBJECTIVE To retrospectively study the clinical efficacy and safety of sulbactam sodium in treatment of extensively drug resistant Acinetobacter baumannii(XDRAB) infection.METHODS Collect cases of XDRAB infection treated with sulbactam Sodium in our hospital from January 2014 to January 2016. Basic information of patients, infection sites, therapeutic strategies, drug combination, clinical outcomes and adverse reactions were analyzed retrospectively.RESULTS A total of 7 cases were collected, including 4 cases of pulmonary infection, 2 cases of intracranial infection, 1 case of abdominal infection, therapeutic strategies for sulbactam sodium-based combination therapy. The total mortality rate was 42.8%; 1 case showed adverse drug reactions may correlated with sulbactam sodium.CONCLUSION Mortality associated with XDRAB infection is high,and the clinical outcome is associated with host factors, because this article included in the number of cases is less, so difficult to evaluate the effectiveness of sulbactam sodium. Sulbactam sodium can be associated with other antimicrobial drugs for the treatment of XDRAB infection and provided more choices.
������, ���, ��ǫ, ����, ÷��, �Ų�. ���̹�����Ʒ���ҩ���������˾���Ⱦ���ٴ���Ч�۲�Ͱ�ȫ�Գ�̽[J]. �й�ҩѧ��־, 2017, 52(11): 981-985.
GUO Xiao-long, WU Bin, ZHANG Qian, HU Yang, MEI Dan, ZHANG Bo. Clinical Efficacy and Safety Preliminary Study of Sulbactam Sodium in Treatment of Extensively Drug Resistant Acinetobacter baumannii Infection. Chinese Pharmaceutical Journal, 2017, 52(11): 981-985.
PELEG A Y. Optimizing therapy for Acinetobacter baumannii[J].Semin Respir Crit Care Med,2007,28(6):662-671.
[4]
CHEN B Y,HE L X,HU B J,et al.Chinese expert consensus on diagnosis and treatment of Acinetobacter baumannii infection and prevention and control[J].China Med Pharm(�й�ҽҩ��ѧ),2012,2(8):3-8.
[5]
Writing Group of Guidance for Clinical Trials of Anti-bacterial.Drugs guidance for clinical trials of anti-bacterial drugs[J].Chin J Clin Pharm(�й��ٴ�ҩ��ѧ��־),2014,30(9):844-856.
POGUE J M, MANN T, BARBER K E, et al.Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management[J].Expert Rev Anti Infect Ther,2013,11(4):383-393.
[8]
HU F P,ZHU D M, WANG F, et al.CHINET 2014 surveillance of bacterial resistance in China[J].Chin J Infect Chemother(�й���Ⱦ�뻯����־),2015,15(5):401-410.
[9]
BETROSIAN A P,FRANTZESKAKI F,XANTHAKI A,et al.High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii[J].Scand J Infect Dis,2007,39(1):38-43.
[10]
MUNOZ-PRICE L S,ROBERT A W.Acinetobacter Infection[J].N Eng J Med,2008,358:1271-1281.
[11]
LEMOS E V,DE LA HOZ F P,EINARSON T R,et al.Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis[J].Clin Microbiol Infect,2014, 20(5):416-423.
[12]
LEE H Y,CHEN C L,WU S R,et al.Risk factors and outcome analysis of Acinetobacter baumannii complex bacteremia in critical patients[J].Crit Care Med,2014,42(5):1081-1088.
[13]
KANG G,HARTZELL J D,HOWARD R,et al.Mortality associated with Acinetobacter baumannii complex bacteremia among patients with war-related trauma[J].Infect Control Hosp Epidemiol Jan,2010,31(1):92-94.
[14]
LIN H S, LEE M H, CHENG C W,et al.Sulbactam treatment for pneumoniainvolving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex[J].Infect Dis,2015, 47(6):370-378.
[15]
KIFFER C R,SAMPAIO J L,SINTO S,et al.In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii[J].Diagn Microbiol Infect Dis,2005, 52(4):317-322.
[16]
FALAGAS M E,KASIAKOU S K.Colistin: the revival of poly-myxins for the management of multidrug-resistant gram-negative bacterial infections[J].Clin Infect Dis,2005,40(9):1333-1341.
[17]
BETROSIAN A P,FRANTZESKAKI F,XANTHAKI A,et al. Efficacy and safety of high-dose ampicillin/sulbactam vs.colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia[J].Infect Jun,2008,56(6):432-436.
2017, Vol. 52 
